Vaccines have produced one of the largest increases in the age of life expectancy in human history. However massive challenges remain, with 17 million deaths per year due to infectious disease – mostly in the developing-world. This forum will introduce three distinguished speakers pioneering approaches to help address this important and pressing challenge. Professors Ian Frazer (co-inventor of the Human Papilloma Virus [HPV] vaccine), Mark Kendall (inventor of the Nanopatch) and Robert Booy (vaccine clinical trials researcher) will discuss key hurdles holding back improving the reach of vaccines for the developing world; and debate current and emerging approaches with the most promise to help overcome them. As a point of focus, the Nanopatch developing-world vaccine project will be discussed: taking Nanopatches to Papua New Guinea for the delivery of HPV vaccines.  


Professor Mark A. F. Kendall
Bachelor of Mechanical Engineering (Hons I UQ), 1993
Doctor of Philosophy (Mechanical Engineering UQ)

Professor Kendall (Bachelor of Mechanical Engineering (Hons I UQ), 1993, Doctor of Philosophy (Mechanical Engineering UQ)) is a biomedical engineer. He is internationally-recognized as a leader in the field of vaccine and drug delivery - culminating from his focused 15 years of research and development in the area. Mark's research has been widely published (>200 papers), while his innovation lies not only in the generation of novel ideas (an inventor of 96 patents), but also in his ability to take those ideas forward towards medical device products. Upon completion of his PhD at UQ in the field of hypervelocity aerodynamics, Mark moved to the University of Oxford to work on the idea of applying rockets to fire micro particle vaccines in to the skin (called Biolistics). While also serving as a University Lecturer, Mark successfully advanced his Biolistic technology, with the resultant spinout company (PowderMed) purchased for $400 million by Pfizer in 2006. In 2006, Mark returned to the University of Queensland for a Professorial position after 8 years at the University of Oxford. At UQ, Mark and his team advanced the Nanopatch needle-free delivery system from an idea to proving vast improvements to several vaccines. This led to Mark founding Vaxxas in 2011, a spin out company with $15 M of investment consortium funding to commercialise the Nanopatch as a medical device product for widespread use in humans. In addition to his UQ Professorial position, Mark is a Vaxxas Director and Chief Technology Officer. Professor Kendall has received many prestigious accolades for his research, leadership and innovation. These include: Younger Engineer of Britain 2004, the 2008 Australian Medical Researcher Award, the 2011 Australian Museum Eureka Prize for Interdisciplinary Research, the inaugural 2011 Australian Innovation Challenge overall prize winner. Most recently, in 2012 Professor Kendall was awarded a a Rolex Laureate - selected as one of just five Laureates from more than 3500 international applicants. He is using this award to progress the Nanopatch for developing world use.

Professor Ian Frazer AC, FRS, FAA 
Chief Executive Officer (CEO) and Director of Research of the Translational Research Institute (TRI) in Brisbane, Australia.
In his role as CEO, Professor Frazer is charged with leading the $354 million TRI to achieve its mission of being Australia’s first institute, and one of only a few in the world, to research, trial and manufacture breakthrough drugs in the one location. The TRI accommodates up to 650 researchers from the four TRI partners: The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and the Princess Alexandra Hospital. Internationally renowned for the co-creation of the technology for the cervical cancer vaccines, Professor Frazer began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister's Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and was recently elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours.

Professor Robert Booy
Head of the Clinical Research team at the National Centre for Immunisation Research and Surveillance (NCIRS)
Professor Robert Booy is Head of the Clinical Research team at the National Centre for Immunisation Research and Surveillance (NCIRS) which he joined in 2005. He is a medical graduate of the University of Queensland (1984) and trained in Paediatrics at the Royal Children's Hospital, Brisbane. His MD is based on Hib epidemiology and immunisation research in Oxford during the early 1990s. He held a range of positions in the UK including Professor of Child Health with the University of London from 1999; He was earlier a Lecturer in Paediatric Infectious Diseases at St Mary’s Hospital, London; and was the recipient of a Wellcome training fellowship in epidemiology focusing on genetic factors important in meningococcal disease. Professor Booy’s research interests extend from understanding the genetic basis of susceptibility to, and severity of, infectious diseases especially influenza and invasive disease caused by encapsulated organisms, to the clinical, public-health, social and economic burden of these diseases, as well as means by which to control serious infections through vaccines, drugs and non-pharmaceutical measures. Over the past 12 years, Professor Booy has been increasingly recognised as an expert in the influenza field. In addition he has led intervention trials with new vaccines, new vaccine delivery methods and alternate methods for preventing disease.

Special Guest

Dr Geoff Garrett AO
Queensland Chief Scientist

Dr Geoff Garrett AO was appointed Queensland Chief Scientist from January 2011, following the retirement of Professor Peter Andrews AO. A Cambridge graduate in metallurgy and an academic for 13 years, Geoff led two of the world's major national research institutions - CSIR in South Africa (1995-2000) and CSIRO in Australia (2001-2008). A former South African 'Engineer of the Year' (1999), he is a recipient of the Centenary Medal for service to Australian society through science. In June 2008 he was appointed as an Officer of the Order of Australia (AO) in the Queen's Birthday Honours List. 


Professor Peter Gray
Director, Australian Institute of Bioengineering and Nanotechnology (AIBN), UQ
Professor Peter Gray was appointed the inaugural director of the Australian Institute of Bioengineering and Nanotechnology (AIBN) at the University of Queensland in 2003. Professor Gray has had commercial experience in the USA working for Eli Lilly and Co and for the Cetus Corporation as well as previously holding academic positions at University College London, and at the University of California, Berkeley. Professor Gray was one of the founders and is a past President of the Australian Biotechnology Association, AusBiotech. He is a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE) and has twice been named as one of Australia’s 100 Most Influential Engineers. Awarded the Centenary Medal by the Australian Government in 2001. Peter is a Vice-President of ATSE, and serves on the Boards of Biopharmaceuticals Australia Pty Ltd, ACYTE Biotechnology Pty Ltd, Stem Cells Ltd, ECI Inc, New York, and a number of State and Federal Government Councils and Committees. Read more

Global Leadership Series 2013: Improving the Reach of Vaccines to the Developing World with Nanopatches from UQ Journalism & Communication on Vimeo.

About Global Leadership Series

The Global Leadership Series (GLS) is a lively program of events for alumni and community members. Join us for lectures and discussions with the best of the best UQ-related speakers on matters that impact your community and shape your ideas of the world.

The series is an opportunity for you to engage with great minds on global matters, participate in thought-provoking discussions and network with UQ alumni and community members. All alumni, parents, community members and friends are welcome to attend the Global Leadership Series events.

Listen to podcasts of previous GLS events click here